Alireza Farabi, MD
Infectious Disease · Las Vegas, NVNPI 1598889008
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $450,515 of the $587,954 with a category attached, or 76.6%. 17 manufacturers reported payments, led by Viiv Healthcare Company at 54.8% of the total. Among infectious disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,166 payments — averaging $504.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$322K
- Gilead$150K
- Janssen Products, LP$43K
- Merck$36K
- Napo Pharmaceuticals Inc$21K
- Theratechnologies Inc.$9K
- plus $6K from 11 others
Across 110 payments — averaging $12,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$540K
- Merck$341K
- Theratechnologies Inc.$237K
- Viiv Healthcare Company$109K
- GSK$98K
- Gilead$79K
What the payments were for
- Consulting fees$65,15311%
- Speaking & faculty fees$450,51577%
- Travel & lodging$42,1907%
- Food & beverage$29,5155%
- Education$5810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 470 | $322,365 |
| Gilead | 331 | $150,295 |
| Janssen Products, LP | 30 | $43,427 |
| Merck | 111 | $35,999 |
| Napo Pharmaceuticals Inc | 52 | $20,763 |
| Theratechnologies Inc. | 22 | $9,052 |
| AbbVie(2 entities) | 30 | $1,848 |
| GSK | 9 | $1,429 |
| Johnson & Johnson(2 entities) | 65 | $1,125 |
| Astellas Pharma US Inc | 21 | $727 |
| Kowa Pharmaceuticals America, Inc. | 10 | $316 |
| Janssen Scientific Affairs, LLC | 2 | $205 |
| EMD Serono, Inc. | 5 | $159 |
| Abbott | 2 | $137 |
| Amarin Pharma, Inc. | 4 | $64 |
| Paratek Pharmaceuticals, Inc. | 1 | $26 |
| Concordia Pharmaceuticals Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$587,954 in reported general payments places this provider in the 95th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 902 | $3,672,391 |
| CabenuvaCabotegravir/Rilpivirine | 240 | $1,600,165 |
| DovatoDolutegravir Sodium/Lamivudine | 413 | $1,220,679 |
| TivicayDolutegravir Sodium | 295 | $695,618 |
| JulucaDolutegravir/Rilpivirine | 181 | $653,706 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 127 | $603,446 |
| TrogarzoIbalizumab-Uiyk | 37 | $289,329 |
| PifeltroDoravirine | 131 | $255,307 |
| PrezcobixDarunavir/Cobicistat | 100 | $249,199 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 56 | $215,955 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 29 | $118,601 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $107,340 |
| RukobiaFostemsavir Tromethamine | 11 | $103,512 |
| MytesiCrofelemer | 17 | $40,764 |
| IsentressRaltegravir Potassium | 20 | $38,921 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyCabenuva, Dovato, Tivicay, Juluca, Rukobia | $322,365 | $4,273,6801,140 claims |
| GileadBiktarvy, Genvoya, Descovy | $150,295 | $3,898,333978 claims |
| Janssen Products, LPSymtuza | $43,427 | $603,446127 claims |
| MerckPifeltro, Isentress, Isentress Hd | $35,999 | $332,873169 claims |
| Theratechnologies Inc.Trogarzo | $9,052 | $289,32937 claims |
| Johnson & JohnsonPrezcobix | $1,125 | $249,199100 claims |
| Napo Pharmaceuticals IncMytesi | $20,763 | $40,76417 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $316 | $13,28037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 infectious disease providers in Nevada.
Other infectious disease in Las Vegas
- Dhiresh JoshiLas Vegas$96K
- Shaker ItaniLas Vegas$52K
- Dhaval ShahLas Vegas$27K
- Alka RebentishLas Vegas$23K
- Ronald ShockleyLas Vegas$13K
- Chukwudum UcheLas Vegas$13K
- John OreillyLas Vegas$8K
- Li-Chien ChenLas Vegas$8K
- Naima ZaheerLas Vegas$7K
- Ricardo Cedeno-MendozaLas Vegas$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.